Background <p>Hallucinations in Parkinson’s disease (PD) are associated with longer disease duration, cognitive impairment, depression, dopaminergic therapy and also poorer quality of life (QoL).</p> Objectives <p>The objectives were (1) to estimate the prevalence and phenomenology of hallucinations and (2) to explore their association with QoL within the PD population in Central Slovakia.</p> Methods <p>Patients with PD (<i>N</i> = 277) were divided into three groups: 1. hallucinating (H), 2. non-hallucinating (NH), 3. non-hallucinating, matched with duration of PD (duration matched, NHdm). The patients completed a questionnaire that revealed the phenomenology of hallucinations. The Parkinson’s Disease Questionnaire (PDQ-39) was used to evaluate QoL.</p> Results <p>The prevalence of hallucinations was 16.97% (<i>N</i> = 47). Visual hallucinations had a cumulative prevalence of 95.7%, with presence (80.8%), passage (53.2%) and well-formed hallucinations (34.0%) being the most common forms. Auditory, olfactory and tactile hallucinations occurred in 27.6, 12.7 and 8.5%, respectively, and multi-modal and multi-sensory hallucinations in 14.9% and 29.8%, respectively. The mean PDQ-39 summary score was higher in the H group (<i>P</i> &lt; 0.0001). QoL was lower in all eight PDQ-39 dimensions, with greater significance in mobility, activities of daily living, emotional well-being, cognition and communication (<i>P</i> &lt; 0.0001 in all). Comparing with the NHdm group, the scores were lower in mobility (<i>P</i> = 0.0019), emotional well-being (<i>P</i> = 0.0010), social support (<i>P</i> = 0.0479) and cognition (<i>P</i> &lt; 0.0001) dimensions.</p> Conclusions <p>This is the first study focusing on the prevalence, phenomenology and impact of hallucinations on QoL in the Slovak population with PD.</p>